Opendata, web and dolomites

NANOBreg SIGNED

A new therapeutic platform based on nanotechnology to promote T- and B-regulatory networks

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NANOBreg project word cloud

Explore the words cloud of the NANOBreg project. It provides you a very rough idea of what is the project "NANOBreg" about.

epitope    autoreactive    action    mhc    career    santamaria    manufacturing    area    complexity    plns    functions    np    autoreactivity    translational    blood    expanding    nsg    specificities    academic    coated    suppressing    separation    therapy    lymph    et    engrafted    pmhc    insights    clinical    pancreatic    purge    cd4    biology    cell    therapeutic    normoglycemia    roles    diabetes    multidisciplinary    cytokines    differentiation    compounds    complexes    collectively    autoantigenic    animals    selectively    strategies    peripheral    mechanisms    interaction    t1d    scalable    critical    sepmag    device    autoantigen    hypotheses    enterprise    bottleneck    immune    mononuclear    nanobreg    recruitment    nanoparticles    mice    recruited    barrier    significance    al    vivo    nodes    presenting    regulatory    humanized    diabetic    bridging    systemic    restore    industry    manner    shown    autoimmune    antigen    enriched    nps    tr1    peptide    blunting    diabetogenic    impairing    patients    immunity    onset    class    inhibit    human    huge    play    loaded    magnetic    cells    cognate    conversion    breg   

Project "NANOBreg" data sheet

The following table provides information about the project.

Coordinator
CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER 

Organization address
address: CALLE ROSSELLO 149 PUERTA BJS
city: BARCELONA
postcode: 8036
website: http://www.idibaps.org/en_index.html

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.idibaps.org
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2015
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2016
 Duration (year-month-day) from 2016-05-01   to  2018-05-13

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

The complexity of autoimmune responses is a barrier to the design of strategies that can selectively purge the immune system of autoreactivity without impairing systemic immunity. Recently, Santamaria et al. have shown that nanoparticles (NPs) coated with type 1 diabetes (T1D)-relevant peptide–MHC (pMHC) complexes can restore normoglycemia in diabetic animals by blunting the diabetogenic autoimmune response without impairing systemic immunity. pMHC class II-NP therapy functions by expanding, in an epitope-specific manner, autoantigen-experienced T-regulatory-1 (TR1) CD4 T-cells that inhibit the recruitment of other autoantigenic specificities by: (1) suppressing autoantigen-loaded antigen-presenting cells in the pancreatic lymph nodes (PLNs); and (2) promoting the differentiation of B-cells into B-regulatory cells. Importantly, they have shown that human T1D-relevant pMHC class II-NPs also promote human TR1 CD4 T-cell formation in NSG mice engrafted with peripheral blood mononuclear cells from recent onset T1D patients.

Here, I propose a multidisciplinary approach to test the following hypotheses: (1) Breg formation is driven by a cognate interaction between TR1 cells and autoreactive B-cells; (2) TR1-derived cytokines play critical roles in TR1-driven Breg conversion in vivo; and (3) the B-cells that are recruited to the PLNs of pMHC-NP-treated humanized NSG mice are enriched for Breg cells. Furthermore, I will work with the enterprise SEPMAG, to design a scalable magnetic separation device for future clinical development of these compounds.

Collectively, NANOBreg will provide new insights into the biology of the TR1-Breg regulatory pathway and will enhance our knowledge on the mechanisms of action of this novel therapeutic approach. In addition, it will address a manufacturing bottleneck by bridging academic research with the manufacturing industry while enhancing my career development in an area of huge potential growth and translational significance.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NANOBREG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NANOBREG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

MegaBiCycle (2019)

The role of megafauna in biogeochemical cycles and greenhouse gas fluxes: implications for climate and ecosystems throughout history

Read More